Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Binod DhakalRavi K NarraSmith GiriAniko SzaboTimothy L SmuntSanjoy GhoseLakshmi Kant PathakMadan AryalMehdi HamadaniSaurabh ChhabraSiegfried JanzAnita D SouzaParameswaran N HariPublished in: Cancer (2020)
The results of this NMA can provide additional guidance for the decision-making process when one is choosing the most appropriate regimen for RRMM.